


YMC


Application Collection

Antibodies & ADCs




IEX
SEC
HIC
RP

Intact mAbs
Digested mAbs
DAR determination
Native LC-MS



Contents

IEX	4
SEC	8
HIC	11
RP	15





(Monoclonal) Antibodies

IEX

BioPro
IEX QA

BioPro
IEX QF

BioPro
IEX SP

BioPro
IEX SF

SEC

YMC-Pack
Diol-200

YMC-Pack
Diol-300

YMC-SEC MAB

HIC

BioPro
HIC HT

BioPro
HIC BF



RP

YMC-Triart
Bio C4

IEX

Ion exchange chromatography (IEX) is one of the standard methods for the characterisation of charge-sensitive biomolecules such as monoclonal antibodies (mAbs). Acidic and basic variants caused by chemical or enzymatic modifications can be separated from the main isoform of the mAb. These antibody variants have to be critically evaluated as differences in impurities and/or degradation products could lead to severe undesirable side effects.

CEX analysis via pH or salt gradient




Column:	BioPro IEX SF (5 µm) 100 x 4.6 mm ID
Part No:	SF00S05-1046WP
Eluents:	pH gradient: A) CX-1 pH Gradient Buffer A* (pH 5.6) B) CX-1 pH Gradient Buffer B* (pH 10.2) Salt gradient: A) 10 mM MES**-NaOH (pH 5.7) B) 10 mM MES**-NaOH (pH 5.7) containing 1 M NaCl
Gradient:	pH: 0–100% B (0–20 min) salt: 0–20% B (0–20 min)
Flow rate:	0.6 mL/min
Temperature:	30 °C
Detection:	Fluorescence: ex 280 nm, em 350 nm
Injection:	2 µL (100 µg/mL each)
Sample:	Natalizumab (Tysabri®) Cetuximab (Erbitux®) Adalimumab (Humira®) Denosumab (Prolia®; XGEVA®)

*commercially available from Thermo Fisher Scientific; 10 times diluted; **MES: (N-morpholino)ethanesulfonic acid


Reference: S. Fekete, A. Beck, D. Guillarme, Characterisation of cation exchanger stationary phases applied for the separations of therapeutic monoclonal antibodies, *J. Pharm. Biomed. Anal.*, 2015, 111, 169–176.

No preconditioning required for reliable results

YMC Accura BioPro IEX SF




Standard PEEK column



Columns: **YMC Accura BioPro IEX SF** (5 μ m) 100 x 4.6 mm ID (bioinert coated hardware)
BioPro IEX SF (5 μ m) 100 x 4.6 mm ID (standard hardware)
Part Nos.: SF00S05-1046PTC
SF00S05-1046WP
Eluent: A) 20 mM NaH₂PO₄-Na₂HPO₄ (pH 6.8)
B) 20 mM NaH₂PO₄-Na₂HPO₄ (pH 6.8) containing 0.2 M NaCl
Gradient: 0-50% B (0-30 min), 0% B (30-45 min)
Flowrate: 0.5 mL/min
Temperature: 25°C
Detection: UV at 280 nm
Injection: 5 μ L
Sample: Bevacizumab (5 mg/mL)
System: bioinert UHPLC

Ideally suited for native IEX-MS




Column: **YMC Accura BioPro IEX SF** (3 μ m) 100 x 2.1 mm ID
Part No.: SF00S03-10Q1PTC
Eluent¹⁾: A) 20 mM CH₃COONH₄-CH₃COOH (pH 5.6)
B) 140 mM CH₃COONH₄-10 mM NH₄HCO₃ (pH 7.4)
Gradient: 20% B (0-2 min), 20-100% B (2-18 min), 100% B (18-22 min)
Flow rate: 0.1 mL/min
Temperature: 25°C
Detection: UV at 280 nm
Injection: 2 μ L
Sample: Trastuzumab (1 mg/mL)
System: bioinert UHPLC

Reference: Y. Yan, A. P. Liu, S. Wang, T. J. Daly und N. Li, Ultrasensitive Characterization of Charge Heterogeneity of Therapeutic Monoclonal Antibodies, Anal. Chem., 2018, 90, 13013-20.

Smaller column IDs that allow lower flow rates and volatile mobile phases are necessities for coupling to mass detection. Such high sensitivity analyses are ideally performed using YMC Accura BioPro IEX columns. Another positive effect is the decreased solvent consumption and lower amount of sample required.

Native online CEX-MS analysis of monoclonal antibodies (IgG1 type)




Column: BioPro IEX SF (5 μ m) 100 x 4.6 mm ID
 Part No.: SF00S05-1046WP
 Eluent: A) 20 mM $\text{CH}_3\text{COONH}_4\text{-CH}_3\text{COOH}$ (pH 5.6)
 B) 140 mM $\text{CH}_3\text{COONH}_4\text{-}10 \text{ mM NH}_4\text{HCO}_3$ (pH 7.4)
 Gradient: 0% B (0–2 min), 0–100% B (2–18 min), 100% B (18–22 min)
 Flow rate: 0.4 mL/min
 (To enable online simultaneous UV and MS detection,
 a post-column analytical splitter (~400:1 ratio) was connected)

Temperature: 45 °C
 Detection: nanospray ionisation-mass spectrometry (NSI-MS)
 Load: 50 μ g
 System: LC ACQUITY UPLC I-Class system (Waters)
 MS) ExactiveTM Plus EMR mass spectrometer
 (Thermo Fisher Scientific)

By courtesy of S. Wang, Regeneron Pharmaceuticals Inc.

Reference: Y. Yan, A. P. Liu, S. Wang, T. J. Daly und N. Li, Ultrasensitive Characterization of Charge Heterogeneity of Therapeutic Monoclonal Antibodies, Anal. Chem., 2018, 90, 13013-20.

Native online AEX-MS of IgG4 type mAbs




Column: BioPro IEX QF (5 μ m) 100 x 4.6 mm ID
 Part No.: QF00S05-1046WP
 Eluent: A) 10 mM ammonium acetate, pH 6.7
 B) 300 mM ammonium acetate, pH 6.8
 Gradient: 0% B (0–2 min), 0–100% B (2–18 min), 100% B (18–22 min)
 Flow rate: 0.4 mL/min
 Temperature: 45 °C intact mAb
 25 °C subunit analysis
 Injection: 5 or 10 μ g mAb sample

Detection: NSI-MS (nanoelectrospray ionisation)
 UV
 Sample: Inhouse IgG4-based mAb, pI=6.6 (Regeneron)
 Setup: Post column stainless-steel tee to direct the majority
 to the UV detector
 Remaining sub-microlitre per minute flow directed
 to the NSI-MS

By courtesy of S. Wang, Regeneron Pharmaceuticals Inc.

Reference: A. Liu, Y. Yan, S. Wang, N. Li, Coupling Anion Exchange Chromatography with Native Mass Spectrometry for Charge Heterogeneity Characterization of Monoclonal Antibodies, Anal. Chem. 2022, 94, 6355–6362.

MS compatible charge variant analysis




Column: BioPro IEX SF (5 µm) 100 x 4.6 mm ID
 Part No: SF00S05-1046WP
 Eluent:
 A) 20 mM $\text{CH}_3\text{COONH}_4\text{-CH}_3\text{COOH}$ (pH 5.6)
 B) 140 mM $\text{CH}_3\text{COONH}_4\text{-10 mM NH}_4\text{HCO}_3$ (pH 7.4)
 Gradients: Depending on the pI of MAb starting with 20–30% B
 Initial %B (0–2 min), initial–100% B (2–18 min), 100% B (18–22 min)
 Flow rate: 0.4 mL/min
 Temperature: ambient
 Detection: Fluorescence: ex 280 nm, em 360 nm

By courtesy of D. Guillarme. Institute of Pharmaceutical Sciences of Western Switzerland (University of Geneva), Geneva, Switzerland


SEC

Due to the sizes of monoclonal antibodies (mAbs, about 150 kDa), size exclusion chromatography (SEC) is a standard technique for analysing mAbs such as bevacizumab (Avastin®). It is also a standard separation mode used in quality control to obtain information about aggregation and/or fragmentation of the mAbs.

Bevacizumab and its fragments and aggregates


Column: YMC-SEC MAB (3 µm, 25 nm) 300 x 4.6 mm ID
 Part No.: DLM25S03-3046WT
 Eluent: 0.1 M phosphate buffer (pH = 7) containing 0.2 M NaCl
 Flow rate: 0.165 mL/min
 Temperature: 25°C

Detection: UV at 280 nm
 Cell path: 10 mm
 Injection: 10 µL (5 mg/mL)
 Sample: Bevacizumab (Avastin®)


Analysis of digested antibody

Column: YMC-SEC MAB (3 µm, 25 nm) 300 x 4.6 mm ID
 Part No.: DLM25S03-3046WT
 Eluent: 0.1 M phosphate buffer (pH = 7) containing 0.2 M NaCl
 Flow rate: 0.165 mL/min

Temperature: 25°C
 Detection: UV at 280 nm
 Injection: 2 µL (3 mg/mL)
 Sample: Humanised monoclonal IgG1 + Papain



Detection of higher molar mass species by MALLS



Column: YMC-SEC MAB (3 µm, 25 nm) 300 x 4.6 mm ID
 Part No.: DLM25S03-3046WT
 Eluent: Phosphate buffer pH 6.6 containing 0.3 M NaCl
 Flow rate: 0.33 mL/min
 Temperature: 25°C
 Detection: MALLS at 90° angle (PSS SLD7100), UV at 280 nm
 Injection volume: 10 µL
 Sample: Bevacizumab (Avastin®) dosage form (10 mg/mL, diluted to 1 mg/mL)
 System: PSS-SECurity GPC systems, 1260 Infinity II
 Software: WinGPC Unichrom


By courtesy of T. Hofe, PSS Polymer Standards Service GmbH, Mainz, Germany.

Four different buffers, a phosphate buffered saline (PBS) pH 7.4 and phosphate buffers pH 6.6 with varying concentrations of NaCl, were used to develop a suitable MALLS detection method for mAbs. A defined minimum ionic strength is necessary to achieve a robust method with good resolution. The phosphate buffer with 0.3 M NaCl appeared to be the most suitable eluent. Compared to UV detection, the MALLS signal shows 2 higher molar mass species, aggregates of bevacizumab, at about 2.0 mL and 2.3 mL elution volume.


Analysis of Antibody-Drug-Conjugates (ADCs)

Brentuximab vedotin and its fragments and aggregates

0.1 M NaH_2PO_4 - Na_2HPO_4 (pH 7.0) containing 0.2 M NaClO_4





0.1 M NaH_2PO_4 - Na_2HPO_4 (pH 7.0) containing 0.2 M NaCl /2-propanol (85/15)




Column: YMC-SEC MAB (3 μm , 25 nm) 300 x 4.6 mm ID
 Part No.: DLM25S03-3046WT
 Eluent: 0.1 M phosphate buffer (pH=7) cont. 0.2 M NaClO_4 ,
 0.1 M phosphate buffer (pH=7) cont. 0.2 M NaCl /2-propanol (85/15)
 Flow rate: 0.165 mL/min
 Temperature: 25°C
 Detection: UV at 280 nm
 Injection: 4 μL (2.5 mg/mL)
 Sample: Brentuximab vedotin (Adcetris®) for injection

By courtesy of Prof. S. Manabe, Hoshi University, Tokyo/Tohoku University, Sendai Japan.

Suitable for Antibody-Drug-Conjugates (ADCs)



Antibody-Drug Conjugate (ADC)



Column: YMC-SEC MAB (3 μm , 25 nm) 300 x 4.6 mm ID
 Part No.: DLM25S03-3046WT
 Eluent: 0.1 M phosphate buffer (pH = 7) containing 0.2 M NaCl /
 2-propanol (85 / 15)
 Flow rate: 0.165 mL/min


Temperature: 25°C
 Detection: UV at 280 nm
 Injection: 4 μL (2.5 mg/mL)
 Sample: SigmaMAb Antibody Drug Conjugate Mimic

YMC-SEC MAB is also suitable for the analysis of Antibody-Drug Conjugates (ADCs). The addition of an organic solvent to the mobile phase can improve the results obtained for ADC analysis.

HIC

Monoclonal antibodies (mAbs) are often analysed using hydrophobic interaction chromatography (HIC) because of their high hydrophobicity. Furthermore, the determination of drug-to-antibody ratios (DAR) of antibody-drug-conjugates (ADCs) such as brentuximab vedotin is important for their therapeutic efficacy and pharmacokinetics. Therefore, control of DAR is a key factor for ADC quality control.

Analysis of oxidised monoclonal antibodies



Column: BioPro HIC BF (4 μm) 100 x 4.6 mm ID

Part No.: BHB00S04-1046WT

Eluent:
A) 100 mM NaH_2PO_4 - Na_2HPO_4 (pH 7.0) containing salt
B) 100 mM NaH_2PO_4 - Na_2HPO_4 (pH 7.0)

Gradient: 40–80% B (0–40 min), 80% B (40–45 min)

Flow rate: 0.3 mL/min


Temperature: 25 °C

Detection: UV at 280 nm

Injection: 5 μL (1.0 mg/mL)

Sample: oxidised NISTmAb

HIC analysis of different monoclonal antibodies using isopropanol as modifier



Column: BioPro HIC BF (4 μm) 100 x 4.6 mm ID

Part No.: BHB00S04-1046WT

Eluent:
A) 20 mM NaH_2PO_4 - Na_2HPO_4 (pH 7.4) containing 1.5 M $(\text{NH}_4)_2\text{SO}_4$
B) 20 mM NaH_2PO_4 - Na_2HPO_4 (pH 7.4) / 2-propanol (85/15)

Gradient: 0–100% B (0–20 min)

Flow rate: 1.0 mL/min


Temperature: 20 °C

Detection: Fluorescence: ex 280 nm, em 360 nm

Injection: 3 μL (2 mg/mL)


By courtesy of D. Guillarme. Institute of Pharmaceutical Sciences of Western Switzerland (University of Geneva), Geneva, Switzerland

Native online HIC-MS analysis of seven different mAbs



*NG: non-glycosylated; PG: partially glycosylated; FG: fully glycosylated.

Separation of two mAbs from their molecular variants



* \square : N-acetylgalactosamine; \bullet : galactose; \diamond : sialic acid

Column: BioPro HIC BF (4 μm) 100 x 4.6 mm ID
 Part No.: BHB00504-1046WT
 Eluent: A) 3 M ammonium acetate in water
 B) 100 % water
 Gradient: 0 %B (0–2 min), 0–90 %B (2–18 min), 90 %B (18–22 min)
 Flow rate: 0.3 mL/min
 Temperature: ambient
 Detection: UV at 280 nm, NSI-MS

Injection: mAb mixture: 3 μL (3–6 μg)
 mAb 8 and mAb 9: 10 μg each
 Sample: Mixture of 7 in-house mAbs at 1–2 mg/mL each
 2 in-house mAbs with molecular variants
 Setup: Post-column makeup flow:
 100 % water at 1.5 mL/min (reducing salt conc. 6-fold)
 Splitter to reduce the flow rate to 1–5 $\mu\text{L}/\text{min}$


By courtesy of S. Wang, Regeneron Pharmaceuticals Inc.

To enable simultaneous UV and MS detection a post-column makeup flow and a splitter were used. The makeup flow decreases the salt concentration while the splitter reduces the flow rate to enable the coupling to MS. A nanospray ionisation (NSI) was chosen because of its high sensitivity and salt tolerance.

Reference: Y. Yan, T. Xing, S. Wang, T. J. Daly, N. Li, Online coupling of analytical hydrophobic interaction chromatography with native mass spectrometry for the characterization of monoclonal antibodies and related products, *J. Pharm. Biomed. Anal.* 186 (2020) 113313.

Highly accurate quantification of ADCs and antibodies

Analysis at various loading amounts





Blank run after each analysis

Column: BioPro HIC HT (2.3 µm) 100 x 4.6 mm ID
 Part No.: BH00SQ3-1046PTH
 Eluent:
 A) 100 mM $\text{NaH}_2\text{PO}_4\text{-Na}_2\text{HPO}_4$ containing 2.0 M $(\text{NH}_4)_2\text{SO}_4$ (pH 7.0)
 B) 100 mM $\text{NaH}_2\text{PO}_4\text{-Na}_2\text{HPO}_4$ (pH 7.0)
 Gradient: 0% B (0–1 min), 0–100% B (1–11 min), 100% B (11–15 min)
 Flow rate: 0.5 mL/min
 Temperature: 25 °C
 Detection: UV at 280 nm

BioPro HIC HT offers higher linearity over wide loading and virtually no carry-over. This contributes to highly accurate quantitation of ADCs and antibodies.

Analysis of ADCs


High DAR →




Column: BioPro HIC BF (4 µm) 100 x 4.6 mm ID
 Eluent:
 A) 50 mM $\text{NaH}_2\text{PO}_4\text{-Na}_2\text{HPO}_4$ (pH 7.0) containing 1.5 M $(\text{NH}_4)_2\text{SO}_4$ /2-propanol (95/5)
 B) 50 mM $\text{NaH}_2\text{PO}_4\text{-Na}_2\text{HPO}_4$ (pH 7.0)/2-propanol (80/20)
 Gradient: 0% B (0–1 min), 0–100% B (1–15 min), 100% B (15–20 min), 0% B (20–30 min)
 Flow rate: 1.0 mL/min
 Temperature: 25 °C
 Detection: UV at 280 nm
 Sample: Antibody-drug-conjugate (courtesy of RIKEN, Japan)

Native online HIC-MS analysis of cys-linked ADCs

[HIC-MS (BPC: base peak chromatogram)]



[Deconvoluted mass spectra]

Column: BioPro HIC BF (4 μ m) 100 x 4.6 mm ID

Part number: BHB00S04-1046WT

Eluent: A) 3 M ammonium acetate in water

B) 2-propanol/water (30/70)

Gradient: 10% B (0–2 min), 10–97% B (2–18 min), 97% B (18–22 min)

Flow rate: 0.3 mL/min

Temperature: ambient

Detection: UV at 280 nm, NSI-MS

Injection: 10 μ g

Sample: SigmaMAb ADC-mimic

Setup: Post-column makeup flow:

100% water at 1.5 mL/min (reducing salt conc. 6-fold)


Splitter to reduce the flow rate to 1–5 μ L/min

By courtesy of S. Wang, Regeneron Pharmaceuticals Inc.

Reference: Y. Yan, T. Xing, S. Wang, T. J. Daly, N. Li, Online coupling of analytical hydrophobic interaction chromatography with native mass spectrometry for the characterization of monoclonal antibodies and related products, *J. Pharm. Biomed. Anal.* 186 (2020) 113313.


High throughput DAR determination by shortening analysis time

1. DAR 0
2. DAR 2
3. DAR 4
4. DAR 6
5. DAR 8



Flow rate 0.5 mL/min

2.5 x faster

Column: BioPro HIC HT (2.3 μ m) 100 x 4.6 mm ID

Part No.: BHH00SQ3-1046PTH

Eluent: A) 20 mM NaH₂PO₄-Na₂HPO₄ containing 1.0 M (NH₄)₂SO₄ (pH 7.0)
B) 20 mM NaH₂PO₄-Na₂HPO₄ (pH 7.0)/2-propanol (85/15)Gradient: 0–100% B (0–15 min), 100% B (15–20 min)
0–100% B (0–6.25 min), 100% B (6.25–8.3 min)

Temperature: 25°C

Detection: UV at 280 nm


Injection: 10 μ LSample: Brentuximab vedotin (Adcetris[®]) (2.5 mg/mL)

RP


Due to their molecular weight of about 150 kDa, intact antibodies are usually analysed by IEX, SEC or HIC. In addition, RP methods have become an easy tool which is compatible with mass spectrometry (MS). However, lack of sensitivity and resolution has been a hurdle in the past. With modern RP phases addressing the requirements of these analytes, it is now easier to find a suitable method. Successful analysis in RP mode for mAbs is enhanced by employing a widepore, temperature-stable stationary phase, such as YMC-Triart Bio C4.

RP analysis of intact monoclonal antibodies


Adalimumab (Humira®, MW: ca. 148 kDa)




Bevacizumab (Avastin®, MW: ca. 148 kDa)



Column: YMC-Triart Bio C4 (3 µm, 30 nm) 150 x 3.0 mm ID
 Part No.: TB30S03-1503PTH
 Eluent:
 A) water/TFA (100/0.1)
 B) acetonitrile/TFA (100/0.1)
 Gradient: 30–60% B (0–15 min), 90% B (15–30 min)
 Flow rate: 0.4 mL/min
 Detection: UV at 220 nm
 Injection: 4 µL
 Sample: Adalimumab (0.5 mg/mL) or Bevacizumab (0.5 mg/mL)

Analysis of different monoclonal antibodies


Column: YMC-Triart Bio C4 (1.9 µm, 30 nm) 50 x 2.1 mm ID
 Part No.: TB30SP9-05Q1PT
 Eluent:
 A) water/TFA (100/0.1)
 B) acetonitrile/TFA (100/0.1)
 Gradient: 25–45% B (0–10 min)
 Flow rate: 0.4 mL/min
 Temperature: 80 °C
 Detection: UV at 280 nm (0.13s, 40Hz)
 Injection: 2 µL (0.5 mg/mL)

Analysis of challenging monoclonal antibodies

Column: YMC-Triart Bio C4 (1.9 µm, 30 nm) 50 x 2.1 mm ID
 Part No.: TB30SP9-05Q1PT
 A) water/TFA (100/0.1)
 B) acetonitrile/TFA (100/0.1)
 Gradient: 25–50% B (0–4 min)
 Flow rate: 0.4 mL/min
 Temperature: 90 °C
 Detection: Fluorescence: ex 280 nm, em 350 nm
 Injection: 0.5 µL

By courtesy of D. Guillarme, Institute of Pharmaceutical Sciences of Western Switzerland (University of Geneva), Geneva, Switzerland


Use of MS compatible conditions for antibody analysis by RP



Column: YMC-Triart Bio C4 (1.9 μ m, 30 nm) 150 x 2.1 mm ID
 Part No.: TB30SP9-15Q1PT
 Eluent: A) water/TFA or formic acid (100/0.1)
 B) acetonitrile/TFA or formic acid (100/0.1)
 Gradient: 10–95% B (0–10 min)


Flow rate: 0.4 mL/min
 Temperature: 80 °C
 Detection: UV at 280 nm (0.13s, 40Hz)
 Injection: 2 μ L (0.5 mg/mL)

LC/MS compatible analysis of monoclonal antibody fragments




Column: YMC-Triart Bio C4 (1.9 μ m, 30 nm) 150 x 2.1 mm ID
 Part No.: TB30SP9-15Q1PT
 Eluent [TFA]: A) water/TFA (100/0.1)
 B) acetonitrile/TFA (100/0.1)
 Gradient [TFA]: 25–50% B (0–10 min), 90% B (10–12.5 min)
 Eluent [formic acid]: A) water/formic acid (100/0.1)
 B) acetonitrile/formic acid (100/0.1)

Gradient [formic acid]: 20–45% B (0–10 min), 90% B (10–12.5 min)
 Flow rate: 0.4 mL/min
 Temperature: 80 °C
 Injection: 4 μ L (0.25 mg/mL)
 Detection: UV at 280 nm
 Sample: mAb Subunit Standard (Waters Corp.)




Commercial monoclonal antibodies by MicroLC-MS

Rituximab (MabThera®)



Bevacizumab (Avastin®)



Column: YMC-Triart Bio C4 (30 nm, 3 µm) 100 x 0.3 mm ID, 1/16" end fittings
 Part No.: TB30S03-10H0AU
 Eluent: A) H₂O + 0.1 % formic acid
 B) acetonitrile + 0.1% formic acid
 Gradient: 20% B (0–2.5 min), 20%–100% B (2.5–4 min),
 100% B (4–5 min), 20% B (5–7 min)
 Flow rate: 15 µL/min
 Temperature: 75 °C, 4 °C Autosampler

Detection: Shimadzu LCMS-9030 QTOF
 Injection: 0.1 µL
 Sample: Rituximab dosage form (10 mg/mL, diluted to 0.1 µg/mL)
 Bevacizumab dosage form (10 mg/mL, diluted to 0.1 µg/mL)
 Bevacizumab solution for patient application (3 mg/mL, diluted to 0.03 µg/mL)
 LC system: Shimadzu Nexera Mikros